| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
319,395,000 |
| Market
Cap: |
1.61(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.97 - $10.87 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
258,574 |
857,044 |
3,037,944 |
| Total Sell Value |
$0 |
$1,699,187 |
$5,857,488 |
$27,280,498 |
| Total People Sold |
0 |
1 |
4 |
8 |
| Total Sell Transactions |
0 |
7 |
43 |
140 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sun Elaine D |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
11,008 |
47,557 |
|
- |
|
| Borgeson Blake |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,016 |
7,089,863 |
|
- |
|
| Dar Zavain |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,016 |
132,893 |
|
- |
|
| Li Dean Y |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,016 |
1,234,618 |
|
- |
|
| Bumpus Namandje |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
11,008 |
47,557 |
|
- |
|
| Michor Franziska |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,016 |
127,053 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,016 |
73,732 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-06-16 |
4 |
D |
$4.92 |
$34,720 |
D/D |
(7,057) |
823,134 |
|
- |
|
| Khan Najat |
Chief R&D Commercial Officer |
• • – |
2025-05-15 |
4 |
D |
$4.25 |
$16,133 |
D/D |
(3,796) |
708,585 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-05-15 |
4 |
D |
$4.25 |
$153,837 |
D/D |
(36,197) |
1,081,253 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-05-15 |
4 |
D |
$4.25 |
$50,609 |
D/D |
(11,908) |
830,191 |
|
- |
|
| Li Dean Y |
Director |
– • – |
2025-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,268 |
79,618 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-04-01 |
4 |
D |
$5.10 |
$135,379 |
D/D |
(26,571) |
842,099 |
|
- |
|
| Dar Zavain |
Director |
– • – |
2025-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,745 |
110,877 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-03-27 |
4 |
AS |
$6.04 |
$836,987 |
D/D |
(138,574) |
1,117,450 |
|
-16% |
|
| Bumpus Namandje |
Director |
– • – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
36,549 |
36,549 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-03-17 |
4 |
D |
$6.84 |
$48,270 |
D/D |
(7,057) |
868,670 |
|
- |
|
| Sun Elaine D |
Director |
– • – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
36,549 |
36,549 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-03-06 |
4 |
AS |
$6.37 |
$127,400 |
D/D |
(20,000) |
1,256,024 |
|
-19% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
1,276,024 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-03-05 |
4 |
AS |
$6.58 |
$131,600 |
D/D |
(20,000) |
1,256,024 |
|
-24% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
1,276,024 |
|
- |
|
| Taylor Ben R |
Chief Financial Officer |
• – – |
2025-02-18 |
4 |
D |
$10.64 |
$115,753 |
D/D |
(10,879) |
875,727 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-02-18 |
4 |
D |
$10.64 |
$182,284 |
D/D |
(17,132) |
1,256,024 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2025-02-06 |
4 |
AS |
$8.12 |
$162,400 |
D/D |
(20,000) |
1,273,156 |
|
-33% |
|
780 Records found
|
|
Page 1 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.37 (6.85%) 
